சீனா தேசிய மருந்து மையப்படுத்தப்பட்ட ப்ரொக்யூர்மெஂட் திட்டம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

®. Next step, the Company will focus on the launch and successful commercialization of BOSHUTAI
®. As manufacturing cost leadership is essential for the success of the product, the company is already working with a number of strategic partnerships across the supply chain to ensure BOSHUTAI
® is manufactured at the lowest cost possible. Additionally, the Company successfully held the BOSHUTAI
® launch conference on 11 December 2020, where more than 60 commercial partners attended the event.
Acarbose was first developed by Bayer in 1975 and launched in Switzerland in 1986 (trade name: Glucobay
®). As the first FDA-approved alpha-glucosidase inhibitor in the world, it entered China in 1994 and is now recommended as a first-line drug for T2D. Acarbose is sold far better in China and Asia than in other western countries due to the high carbohydrate content in Asian cuisine. ....

Frank Zhao , Xu Honglei , Bio Science Group , Science Group Head , National Essential Medicine List , National Basic Medical Insurance , China National Drug Centralized Procurement Scheme , National Medical Products Administration , Science Group , International Diabetes Federation , Bio Science Group Limited The Company , Bio Science Group Limited , Acarbose Tablets , Yingli Executive Director , Acarbose Market Authorization Holder , Uni Bio Science Group , China Diabetes Prevention , Therapy Guide , National Basic Medical , வெளிப்படையான ழோ , உயிர் அறிவியல் குழு , அறிவியல் குழு தலை , தேசிய அவசியம் மருந்து பட்டியல் , தேசிய அடிப்படை மருத்துவ காப்பீடு , சீனா தேசிய மருந்து மையப்படுத்தப்பட்ட ப்ரொக்யூர்மெஂட் திட்டம் , அறிவியல் குழு ,